A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease | MicrobiomeTrials← Back to trialsNCT07332481
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-03-10Est. Completion: 2029-05-24
Enrollment target: 202 participants Locations- Dermatology Research Associates - 300204025, Los Angeles, California, United States
- Cohen Medical Centers, Thousand Oaks, California, United States
- GNP Research at Mark Jaffe, MD, Cooper City, Florida, United States
- Advance Medical Research Center, Miami, Florida, United States
- Diverse Clinical Research LLC, Miami, Florida, United States
- D&H National Research Centers, Inc., Tamarac, Florida, United States
- Clinical Research of West Florida, Inc., Tampa, Florida, United States
- Emory University School of Medicine, Atlanta, Georgia, United States
- Revival Research Institute, LLC, Troy, Michigan, United States
- Allen Arthritis, Allen, Texas, United States
- Arthritis and Rheumatology Research Institute PLLC, Allen, Texas, United States
- Arthritis Care of Texas, Corpus Christi, Texas, United States
- Sapporo City General Hospital - Dept of Rheumatology/Immunology, Sapporo, Hokkaido, Japan
Other microbiome trials you might be interested in
Systemic Lupus Erythematosus
The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-s…
Birmingham, United StatesEst. completion Aug 22, 2025
Systemic Lupus Erythematosus (SLE)
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic…
Phoenix, United StatesCompleted Mar 29, 2030
Phase 2
Recruiting
Cutaneous Lupus Erythematosus (CLE)Systemic Lupus ErythematosusSLESLE (Systemic Lupus)CLE
The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) …
Beverly Hills, United StatesEst. completion Jul 2026